Brief: Imagion Biosystems Says Management Expects R&D Costs To Increase During Remainder Of 2023
30/08/2023 02:19
Aug 30 (Reuters) - Imagion Biosystems Ltd IBX.AX :
* MANAGEMENT EXPECTS RESEARCH AND DEVELOPMENT COSTS TO
INCREASE
DURING REMAINDER OF 2023
Source text for Eikon: ID:nASX5f5HK0
Further company coverage: IBX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imagion Biosystems
See all newsBrief: Imagion Biosystems Resumes Magsense Nanoparticle Manufacturing Capabilities
Brief: Imagion Biosystems Secures AU$3.75M In Capital Raise Following FDA Clearance Of Phase 2 Clinical Trial
Brief: Imagion Biosystems Secures A$3.75 Million In Firm Commitments Under Capital Raising
Australia's Imagion Biosystems falls on discounted placement
Brief: Imagion Biosystems Seeks Trading Halt